11 October 2019 - Sanofi said it would run a program to support part of the cost of Dupixent, a new biologic agent for severe atopic dermatitis, for Korean patients until the drug gets insurance coverage.

The company made the decision regardless of the results of the review on the health insurance for Dupixent, in a meeting of the Health Insurance and Review and Assessment Service (HIRA)’s Pharmaceutical Reimbursement Evaluation Committee on Thursday.

As the discussion with HIRA over the insurance benefit for Dupixent dragged, Sanofi decided to ease the burden for patients receiving Dupixent treatment, it said.

Sanofi-Aventis Korea persuaded the headquarters aggressively to implement the patient support program, industry sources said.

Read Korea Biomedical Review article